[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-disease-chronic-obstructive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-disease-chronic-obstructive":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,39,70,97,134,156,185,206,230,253,279,304,327,342,362,382,407,429,454,475,503,525],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100570847","pooled-analysis-of-single-arm-studies-of-budesonideglycopyrroniumformoterol-bgf-in-routine-care-setting-100570847",false,"NCT06712563","Pooled Analysis of Single-arm Studies of Budesonide\u002FGlycopyrronium\u002FFormoterol (BGF) in Routine Care Setting","Pooled Analysis of Multi-country, Open-label Single-arm, Non-interventional, Multi-center, Cohort Studies of Real-world Outcomes in New Users of Budesonide\u002FGlycopyrronium\u002FFormoterol (BGF) in Routine Care Setting","CHOROS","Inclusion Criteria:\n\n* Patients with moderate to severe COPD and initiating BGF treatment according to the local prescribing guidance and as per their treating physician's recommendation\n* Enrolled in on-going single-arm studies\n* Provided consent for secondary use of data\n\nExclusion Criteria:\n\n* Did not provide consent for secondary use of data","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","OBSERVATIONAL","The CHOROS pooled analysis is a retrospective secondary data use analysis of integrated individual participant data from a series of planned and on-going primary prospective, non-interventional, multi-center studies sponsored by AstraZeneca and conducted in the pulmonary\u002Fprimary care practitioner setting in multiple countries and may include data from the following countries: United Kingdom, Germany, Italy, Greece, Japan, Canada and Romania.",[25],"Pulmonary Disease, Chronic Obstructive","RECRUITING","2026-06-15",{"date":29,"type":30},"2026-06-16","ACTUAL",{"date":32,"type":30},"2025-04-17",{"date":34,"type":21},"2026-12-14",{"name":36,"class":37},"AstraZeneca","INDUSTRY",7,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100574109","benefits-of-epithelial-repair-in-copd-by-induced-pluripotent-stem-cells-ips-100574109","NCT06755008","Benefits of Epithelial Repair in COPD by Induced Pluripotent Stem Cells (iPS)","RepCOPDiPS","General Inclusion Criteria\n\n* Male and female participants aged 18 years or older.\n* Participants with a bronchoscopy indication determined by a pulmonologist (e.g., follow-up exploration, nodule investigation, hemoptysis, cough, sputum production, recurrent bronchitis, or differential diagnosis).\n\nGroup 1 Inclusion Criteria: COPD\n\n* Current or former smokers (≥10 pack-years).\n* Diagnosed with COPD: FEV1\u002FFVC \\\u003C 0.7 (confirmed by spirometry available in the medical file within the past year).\n\nGroup 2 Inclusion Criteria: Smokers without COPD (n=10)\n\n* Current or former smokers (≥10 pack-years).\n* No obstructive ventilatory disorder identified by clinical examination and\u002For (FEV1\u002FFVC \\> 0.7 and FEV1 \\> 70% of predicted values) confirmed by spirometry within the past year.\n\nGroup 3 Inclusion Criteria: Non-smoker controls (n=10)\n\n* Never-smokers or former smokers who quit more than 10 years ago (\\\u003C10 pack-years).\n* No obstructive ventilatory disorder identified by clinical examination and\u002For (FEV1\u002FFVC \\> 0.7 and FEV1 \\> 70% of predicted values) confirmed by spirometry within the past year.\n\nExclusion Criteria:\n\n* Participant with extensive neoplastic disease.\n* Participant with another progressive pulmonary condition (e.g., asthma, tuberculosis, interstitial lung disease, active or recent pulmonary infection).\n* Participant consuming illicit drugs or alcohol.\n* Individual deprived of liberty (by judicial or administrative decision, or under involuntary hospitalization).\n* Individual currently enrolled in another research study with an ongoing exclusion period.\n* Participant with recent psychiatric disorders (e.g., involuntary hospitalization, mental health conditions preventing informed consent, or requiring immediate medical intervention).\n* Adult under legal protection (e.g., guardianship, curatorship, or judicial protection).\n* Participant unable to provide informed consent.\n* Participant not fluent in French and without a trusted person to assist with comprehension.\n* Participant not affiliated with or covered by a social security system.\n* Pregnant or breastfeeding women.\n* Participant refusing to provide consent after being informed.\n* Participant unable or incapable of expressing consent.",{"count":47,"type":21},50,"INTERVENTIONAL",[50],"NA","The aim of this interventional, cross-sectional and pathophysiological experimental study is to evaluate the potential of a patient's induced pluripotent stem (iPS) cells, used prior to the re-differentiation stage, to enable ex vivo repair of the injured epithelium in patients with chronic obstructive pulmonary disease (COPD), smokers without COPD and non-smoking controls.\n\nThe main questions it aims to answer are:\n\n* to evaluate the repair capacity of bronchial epithelium in COPD subjects, using a model of bronchial epithelium reconstituted in air\u002Fliquid interface culture and the iPS model.\n* epithelia repair capacities in normal or aberrant situations, as well as the time required for this repair, and to determine the involvement of grafted iPS cells in epithelia repair in cultured control subjects, smokers without COPD and COPD patients.\n\nResearchers will compare 3 groups of participants (COPD patients, smokers without COPD and non-smokers without COPD) for epithelial repair efficacy between non-grafted ALI cultures and ALI cultures grafted with iPS cells, in order to assess their contribution to epithelial repair.\n\nParticipants will undergo a bronchial fibroscopy (for clinical indications) with two additional biopsies specific to the study.\n\nThis research could lead to breakthroughs in cell-based therapies for COPD, with long-term implications for epigenetic treatments and in vivo applications.",[25],[54,55,56,57,58],"COPD","bronchial epithelium","iPS","repair","Club cell","2026-05-07",{"date":61,"type":30},"2026-05-12",{"date":63,"type":30},"2025-02-19",{"date":65,"type":21},"2028-01-01",{"name":67,"class":68},"University Hospital, Montpellier","OTHER",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100493417","monitoring-of-the-end-tidal-carbon-dioxide-etco2-as-a-severity-criterion-in-copd-exacerbations-100493417","NCT05704881","Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations","Monitoring of the End-tidal Carbon Dioxide (EtCO2 ) as a Severity Criterion in COPD Exacerbations: a Prospective Observational Study","CO2PD","Inclusion Criteria:\n\n* All patient presenting to the emergency department with acute dyspnea and with a history of COPD documented or reported by the patient and\u002For family\n* Male or female≥18 years old who did not oppose to participating in the study\n\nExclusion Criteria:\n\n* Hypotension (SBP \\\u003C 90 mmHg or MBP \\\u003C 65 mmHg)\n* Patient already included in the study during a previous visit to the emergency department\n* Patient already ventilated with invasive or NIV during admission to the emergency department\n* COPD exacerbation rejected after medical and additional examinations\n* Non-communicative or non-French speaking patients, or with impaired comprehension, or with impaired consciousness\n* Protected persons referred to in articles L1121-6 and L1121-8 of French public health code (deprived of liberty, tutorship or curatorship)",{"count":79,"type":21},240,"Although we know that these numbers are underestimated, Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease that affects between 8 and 12% of adults. According to a 2020 WHO report, it is the third most common cause of mortality in developed countries. This disease is punctuated by exacerbations associated with an 8% mortality of hospitalized patients, increased to 24% when the patient is admitted to intensive care unit. Early detection and treatment of these exacerbations appears to be essential to improve patient survival. End-tidal carbon dioxide (EtCO2) is used to assess a patient's respiratory and hemodynamic status. Indeed, EtCO2 is a non-invasive measure that could allow the estimation of arterial carbon dioxide (PaCO2) without performing blood gases, an arterial blood sampling, classically at the radial artery. This study aimed to find an EtCO2 value which at the time of the initial management, would be predictive of a severe COPD exacerbation, as well as PaCO2.",[25,82],"Exacerbation Copd",[84,85,86],"Chronic Obstructive Pulmonary Disease","Capnography","COPD exacerbation","2026-04-14",{"date":89,"type":30},"2026-04-15",{"date":91,"type":30},"2023-03-03",{"date":93,"type":21},"2026-12-03",{"name":95,"class":68},"University Hospital, Grenoble",2,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":48,"phases":109,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100589961","phase-3-depemokimab-as-an-extended-treatment-duration-biologic-in-adults-with-chronic-obstructive-pulmonary-disease-copd-and-type-2-inflammation-endura-2-100589961","NCT06961214","Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab in Adult Participants With COPD With Type 2 Inflammation","ENDURA-2","Inclusion Criteria:\n\n* Participants must be greater than or equal to (\\>=) 40 to less than or equal to (\\\u003C=) 80 years of age, at the time of signing the Informed consent\n* Elevated Blood Eosinophil Count (BEC)\n* Moderate to severe COPD with frequent exacerbations, defined as:\n\n  * A clinically documented history of COPD as defined by the American Thoracic Society\u002FEuropean Respiratory Society for at least 1 year\n  * A post-bronchodilator forced expiratory volume in one second (FEV1)\u002F forced vital capacity (FVC) ratio of \\\u003C 0.70 and a post-bronchodilator FEV1 \\>30 percent (%) and \\\u003C= 80% predicted normal values\n  * A well-documented history of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening\n* COPD assessment test (CAT) score \\>=10 at Visit 1\n* Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \\>=10 pack-years.\n* Participants should be on optimized inhaler therapy, defined as inhaled corticosteroid (ICS) plus Long-acting muscarinic receptor antagonist (LAMA) plus Long-acting beta2-adrenergic receptor agonist (LABA) either as multiple inhalers or a single combination inhaler for at least 6 months prior to Screening Visit 1\n* Body mass index (BMI) \\>=16 kilogram per square meter (kg\u002Fm\\^2)\n* Male and eligible female participants\n\nExclusion Criteria:\n\nThe following subjects are excluded:\n\n* Participants with a current or prior physician diagnosis of asthma\n* Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease\n* Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1\n* Lung resection: Participants with a history of or plan for lung volume reduction surgery \u002F endobronchial valve procedure.\n* Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening Visit 1\n* Continuous oxygen: Participants requiring oxygen supplementation for more than 12 hours per day\n* Cor pulmonale - resulting in right heart failure, severe pulmonary hypertension\n* Chronic hypercapnia requiring Non-invasive positive pressure ventilation (NIPPV) use (including Bi-Level Positive Airway Pressure \\[BiPAP\\] or Continuous Positive Airway Pressure \\[CPAP\\])\n* Unstable cardiovascular disease or arrhythmia\n* Parasitic Infection: Participants with a known, pre-existing parasitic infection within 6 months of Screening (Visit 1)","40 Years","80 Years",{"count":108,"type":21},960,[110],"PHASE3","Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.",[25],[114,115,116,117,54,118,119,120,121,122,123],"Depemokimab","GSK3511294","Eosinophilic phenotype","Chronic obstructive pulmonary disease","Moderate COPD","Severe COPD","Uncontrolled Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","Exacerbations","Placebo","Type 2 inflammation","2026-04-06",{"date":126,"type":30},"2026-04-09",{"date":128,"type":30},"2025-06-23",{"date":130,"type":21},"2029-08-21",{"name":132,"class":37},"GlaxoSmithKline",159,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":48,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100494432","pragmatic-trial-to-enhance-quality-safety-and-patient-experience-in-copd-100494432","NCT05718102","Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD","EQuiP COPD","Inclusion Criteria:\n\n* Participants may be PCP physicians and advance practice providers (APP) practicing at participating sites, and their patients who are diagnosed with or treated for COPD based on the following criteria:\n\n  1. Recent discharge from hospital for COPD exacerbation\n  2. Recent outpatient exacerbation (emergency room (ER), primary care)\n  3. Received prescription for an inhaled corticosteroid (ICS) but does not meet criteria for ICS use\n  4. Diagnosis of COPD and\u002For treatment and active smoker not receiving smoking cessation aide\n  5. Treatment for COPD without evidence of spirometry within 10 years, or no airflow obstruction on existing spirometry",{"count":142,"type":21},4000,[50],"Background: Over 26 million Americans have chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in the United States. Unfortunately, few patients receive proven therapies and many receive therapies known to have safer alternatives. One major reason is the competing demands of primary care providers (PCPs) who manage 90% of patients with COPD. The research team has developed a population management approach where pulmonary specialists provide evidence-based recommendations as an E-consult with unsigned orders to PCPs. PCPs can then quickly review the E-consult and sign, modify, or discontinue these orders. The investigators found this intervention led to marked improvements in the quality-of-care delivered and patients' COPD-related quality-of-life. While promising, this approach is limited by a paucity of pulmonary providers nationwide. Clinical pharmacists are 20 times more prevalent as pulmonary specialists and some regions of VA (VISN 17, COPD Cares) have assigned clinical pharmacists a role in the management of patients with COPD. However, the relative effectiveness of pharmacist-led management is yet to be established.\n\nStudy Description: This study tests population management for COPD provided by pharmacists relative to pulmonary specialists. The investigators are conducting a cluster randomized clinical trial at five medical centers and their associated clinics within the Department of Veterans Affair. Study staff will randomize PCPs to population management conducted by either pulmonary specialists or pharmacists. Within PCPs' panels, study staff will use VA electronic health record to identify patients with evidence of COPD. Pulmonologists and pharmacists will review these patients and provide guideline-based recommendations to PCPs. Pulmonary specialists and pharmacists will then deliver evidence-based recommendations through E-consults coupled with unsigned orders for primary care providers to sign, modify or decline.\n\nOutcomes: Investigators will assess if proactive, population management recommendations by clinical pharmacists and pulmonary specialists lead to non-inferior outcomes for patients with COPD. The primary outcome will be a composite endpoint of COPD exacerbation, pneumonia, hospitalization, or death six month after intervention. Secondary outcomes will include 1) the proportion of guideline recommended therapies received by patients, 2) COPD-related quality-of-life as measured by the Clinical COPD Questionnaire, and 3) PCP acceptance of recommendations, 4) each individual outcome within the primary composite endpoint above, and 5) patient- and caregiver-incurred costs.",[25],"2026-03-20",{"date":148,"type":30},"2026-03-25",{"date":150,"type":30},"2023-05-15",{"date":152,"type":21},"2027-01-01",{"name":154,"class":68},"Seattle Institute for Biomedical and Clinical Research",5,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":48,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":69},"100484806","a-study-of-the-effect-of-a-nurse-navigator-program-on-high-risk-patients-100484806","NCT05592847","A Study of the Effect of a Nurse Navigator Program on High Risk Patients","The Effect of a Nurse Navigator Program on Readmission Rates for Patients With Elevated BMI, COPD, CHF, Dialysis Use, and H\u002Fo Alcohol Abuse","Inclusion Criteria:\n\n\\- Require total or partial hip or knee replacement and have one or more of the following diagnosis: Heart Failure (HF); Chronic obstructive pulmonary disease (COPD); Dialysis; Alcohol Abuse; Low BMI.\n\nExclusion Criteria:\n\n\\- Decrease cognitive capacity to consent to the study.",{"count":164,"type":21},300,[50],"The purpose of this study is to examine if educational intervention in high risk patients can lead to decreased hospital readmissions when compared to patients who are not in the intervention program. Additionally, to determine patient satisfaction with the educational program.",[168,169,170,171,25,172,173,174],"Patient Readmission","Arthroplasty, Replacement, Knee","Arthroplasty, Replacement, Hip","Heart Failure","Renal Insufficiency","Body Mass Index","Alcoholism","NOT_YET_RECRUITING","2026-03-17",{"date":178,"type":30},"2026-03-19",{"date":180,"type":21},"2027-01",{"date":182,"type":21},"2027-06",{"name":184,"class":68},"Mayo Clinic",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":106,"enrollmentInfo":192,"targetDuration":4,"studyType":48,"phases":194,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":69},"100459644","phase-3-trial-to-determine-effective-aspirin-dose-in-copd-100459644","NCT05265299","Trial to Determine Effective Aspirin Dose in COPD","Randomized Trial to Determine Effective Aspirin Dose in COPD","Inclusion Criteria:\n\n* Age ≥40 years\n* Former smoker\n* At least 10 pack-year smoking history\n* Post-bronchodilator ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1\u002FFVC) \\\u003C 0.7\n\nExclusion Criteria:\n\n* History of myocardial infarction, percutaneous coronary intervention, or stroke\n* Currently taking antiplatelet therapy (other than aspirin 81mg) or anticoagulant medication\n* Contraindication to aspirin (including low platelet count, hematocrit \\\u003C25%, known aspirin-exacerbated respiratory disease, bleeding disorder, history of bleeding or gastrointestinal (GI) ulcer, coagulopathy, or major surgery within 6 weeks before randomization)\n* Oral corticosteroids within the past 6 weeks\n* Currently taking immunosuppressant medication\n* Active malignancy (other than non-melanoma skin cancer)\n* Uncontrolled hypertension\n* Pregnant or planning pregnancy in the next year\n* Plans to move residence away from the immediate area within the next 3 months",{"count":193,"type":21},48,[110],"Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States. Current treatments for COPD focus on inhaler therapies that do not address manifestations of the disease on other organ systems. Platelets, which are small blood cells that typically help with clotting, are also involved in generalized inflammation and dysfunctionality of immune cells when these cells become activated. Activated platelets have long been known to play a role in the development of cardiovascular disease. However, there is recent evidence that activated platelets may be involved in worse respiratory symptoms in COPD independent of cardiovascular disease. Individuals with COPD who are taking aspirin, which is an antiplatelet agent that blocks activation of platelets, have been shown to have improved respiratory symptoms, fewer COPD flares, and lower mortality. The investigators' ultimate goal is to study whether aspirin use improves respiratory symptoms independent of cardiovascular disease. The investigators are conducting the current pilot trial to determine the optimal dose of aspirin that blocks platelet activation in this population and investigate whether there are any blood or urine tests that can help with understanding response to therapy. The results will inform the design of a larger trial investigating clinical outcomes. The investigators hypothesize that daily low-dose aspirin will not be sufficient to adequately suppress platelet activation and that an aspirin dose of at least 162mg daily will be necessary.",[25],"2026-03-13",{"date":199,"type":30},"2026-03-16",{"date":201,"type":30},"2023-05-16",{"date":203,"type":21},"2026-12",{"name":205,"class":68},"Johns Hopkins University",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":48,"phases":214,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":69},"100624908","functional-assessment-and-pulmonary-rehabilitation-challenges-and-perspectives-for-comprehensive-care-100624908","NCT07415746","Functional Assessment and Pulmonary Rehabilitation: Challenges and Perspectives for Comprehensive Care","Inclusion Criteria:\n\n* Age 40 years or older.\n* Both sexes are eligible (men and women).\n* Clinically diagnosed COPD, clinically stable, classified in Stages I, II, III or IV of GOLD (Global Initiative for Chronic Obstructive Lung Disease).\n* Ability to understand and provide the signed Informed Consent Form to participate in the study.\n\nExclusion Criteria:\n\n* Physical limitations and\u002For cognitive impairment that prevent the execution of the study protocol.\n* Currently engaged in physical therapy treatment and\u002For physical activity that may interfere with the study results.\n* Presence of severe, uncontrolled, or disabling comorbidities.",{"count":213,"type":21},46,[50],"Individuals with Chronic Obstructive Pulmonary Disease (COPD) present with respiratory muscle dysfunction, characterized by reduced diaphragmatic contractility and mobility due to pulmonary hyperinflation, oxidative stress, and systemic inflammation. Effective assessment of diaphragmatic function is crucial for monitoring progress in pulmonary rehabilitation programs. This study aims to evaluate diaphragmatic function and mobility in COPD patients undergoing pulmonary rehabilitation with inspiratory muscle training, using ultrasound, and to identify associations between diaphragmatic dysfunction and clinical symptoms such as dyspnea and fatigue. A randomized clinical trial will be conducted to investigate the impact of rehabilitation on diaphragmatic function, correlating it with pulmonary function and physical performance.",[25],[25,218,219,220],"Rehabilitation","Ultrasonography","Breathing Exercises","2026-02-09",{"date":223,"type":30},"2026-02-17",{"date":225,"type":21},"2026-03",{"date":227,"type":21},"2026-10",{"name":229,"class":68},"Universidade do Estado do Pará",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":236,"sex":17,"minAge":18,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":48,"phases":240,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":69},"100485848","hypoxia-and-heart-rate-variability-100485848","NCT05606406","Hypoxia and Heart Rate Variability","Healthy Participants\n\nInclusion Criteria:\n\n• Ability to provide consent\n\nExclusion Criteria:\n\n* BMI \\> 40 kg\u002Fm2\n* Prevalent myocardial infarction, coronary revascularization, heart failure, and stroke\n* Unstable medical conditions that may preclude enrollment in the protocol such as: uncontrolled angina and\u002For congestive heart failure, uncontrolled blood pressure or resistant hypertension, cancer, and active psychiatric disease (e.g., major depression)\n\nNocturnal Hypoxemia\n\nInclusion Criteria:\n\n* Ability to provide consent\n* Chronic respiratory condition resting Sat \\\u003C 95% off oxygen\n\nExclusion Criteria:\n\n* BMI \\> 40 kg\u002Fm2\n* Prevalent myocardial infarction, coronary revascularization, heart failure, and stroke\n* Unstable medical conditions that may preclude enrollment in the protocol such as: uncontrolled angina and\u002For congestive heart failure, uncontrolled blood pressure or resistant hypertension, severe chronic obstructive pulmonary disease, cancer, and active psychiatric disease (e.g., major depression)",true,"70 Years",{"count":239,"type":21},70,[50],"The purpose of this study is to evaluate how variations in oxygen demands may change heart electrical activity in individuals with and without oxygen dependence.",[25,243],"Hypoxia","2026-02-02",{"date":246,"type":30},"2026-02-05",{"date":248,"type":21},"2026-05-30",{"date":250,"type":21},"2027-12-30",{"name":252,"class":68},"University of Miami",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":261,"enrollmentInfo":262,"targetDuration":4,"studyType":48,"phases":264,"briefSummary":265,"conditions":266,"keywords":267,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":278},"100606575","phase-3-evaluating-the-efficacy-and-safety-of-initiating-depemokimab-early-therapy-in-chronic-obstructive-pulmonary-disorder-copd-with-type-2-inflammation-100606575","NCT07177339","eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation","A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study of the Efficacy and Safety of Early Depemokimab Initiation as add-on Treatment in COPD Patients With Type 2 Inflammation","VIGILANT","Inclusion Criteria:\n\n* Male or eligible female participants\n* Eosinophilic phenotype measured using Blood Eosinophil Count (BEC)\n* Moderate to severe COPD, defined as\n\n  * A clinically documented history of COPD for at least 1 year\n  * A post-salbutamol Forced expiratory volume in one second (FEV1)\u002FForced vital capacity (FVC) ratio of less than (\\\u003C)0.70 and a post-salbutamol FEV1 greater than (\\>)30 percent (%) and \\\u003C80% predicted normal values\n* Elevated risk for exacerbations, defined as\n\n  * A well-documented history of only 1 moderate COPD exacerbation in the prior 12 months and\n  * The presence of risk factors for future exacerbations\u002Fdeterioration such as:\n  * Modified Medical Research Council (mMRC) dyspnea score \\>= 2\n  * COPD Assessment Test (CAT) \\>= 15\n  * Post-bronchodilator FEV1 \\\u003C 50% predicted\n  * Chronic bronchitis\n* Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \\>=10 pack-years at Screening.\n* Dual (Inhaled corticosteroid (ICS)+ Long-acting beta2-adrenergic receptor agonist \\[LABA\\] or LABA+ Long-acting muscarinic receptor antagonist \\[LAMA\\]) or triple (ICS+LABA+LAMA) inhaler therapy as assessed by the investigator for at least 3 months\n* Body mass index (BMI) \\>=16 kilograms per square meter (kg\u002Fm\\^2)\n\nExclusion Criteria:\n\n* The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of lung disease, and clinical manifestations of lung disease where primary diagnosis is not COPD are excluded\n\n  * Participants with a current or prior physician diagnosis of asthma\n  * Participants with childhood asthma are permitted, provided that childhood asthma has resolved before 18 years of age and has not recurred\n* Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease.\n* COPD severity: Participants with more than one moderate exacerbation or severe exacerbation in the past 12 months prior to Visit 1\n* COPD stability: Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Visit 1\n* Lung resection: Participants with a history of, or plan for lung volume reduction surgery\u002Fendobronchial valve procedure\n* Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1\n* Chronic hypercapnia requiring non-invasive positive pressure ventilation (NIPPV) use including Bi-Level Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP) are excluded\n* Continuous oxygen: Participants requiring oxygen supplementation for COPD","75 Years",{"count":263,"type":21},1196,[110],"Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.",[25],[114,268,54,123,116,269],"Chronic Obstructive Pulmonary Disorder","Exacerbation","2025-11-24",{"date":272,"type":30},"2025-11-25",{"date":274,"type":30},"2025-10-20",{"date":276,"type":21},"2029-12-14",{"name":132,"class":37},6,{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":106,"enrollmentInfo":287,"targetDuration":4,"studyType":48,"phases":289,"briefSummary":290,"conditions":291,"keywords":292,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":303},"100589798","phase-3-depemokimab-as-an-extended-treatment-duration-biologic-in-adults-with-chronic-obstructive-pulmonary-disease-copd-and-type-2-inflammation-endura--1-100589798","NCT06959095","Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)","A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab In Adult Participants With COPD With Type 2 Inflammation","ENDURA -1","Inclusion Criteria:\n\n* Participants must be greater than or equal to (\\>=) 40 to less than or equal to (\\\u003C=) 80 years of age, at the time of signing the informed consent.\n* Elevated blood eosinophil count (BEC).\n* Moderate to severe COPD with frequent exacerbations, defined as:\n* A clinically documented history of COPD as defined by the American Thoracic Society\u002FEuropean Respiratory Society for at least 1 year\n* A post-bronchodilator forced expiratory volume in one second (FEV1)\u002Fforced vital capacity (FVC) ratio of less than (\\\u003C) 0.70 and a post- bronchodilator FEV1 \\>30 percent (%) and \\\u003C= 80% predicted normal values\n* A well-documented history of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening\n* COPD assessment test (CAT) score \\>=10 at Visit 1.\n* Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \\>=10 pack-years.\n* Participants should be on optimized inhaler therapy, defined as inhaled corticosteroid (ICS) plus Long-acting muscarinic receptor antagonist (LAMA) plus Long-acting beta2-adrenergic receptor agonist (LABA) either as multiple inhalers or a single combination inhaler for at least 6 months prior to Screening Visit 1.\n* Body mass index (BMI) \\>=16 kilogram per square meter (kg\u002Fm\\^2).\n* Male or eligible female participants.\n\nExclusion Criteria:\n\nThe following subjects are excluded:\n\n* Participants with a current or prior physician diagnosis of asthma.\n* Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease.\n* Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1.\n* Lung resection: Participants with a history of, or plan for lung volume reduction surgery \u002F endobronchial valve procedure.\n* Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening Visit 1.\n* Continuous oxygen: Participants requiring oxygen supplementation for more than 12 hours per day.\n* Cor pulmonale - resulting in right heart failure, severe pulmonary hypertension\n* Chronic hypercapnia requiring Non-invasive positive pressure ventilation (NIPPV) use (including Bi-Level Positive Airway Pressure \\[BiPAP\\] or Continuous Positive Airway Pressure \\[CPAP\\]).\n* Unstable cardiovascular disease or arrhythmia.\n* Parasitic Infection: Participants with a known, pre-existing parasitic infection within 6 months of Screening (Visit 1).",{"count":288,"type":21},981,[110],"Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.",[25],[114,115,116,117,293,118,119,294,121,122,123],"(COPD)","Uncontrolled Moderate to Severe Chronic Obstructive Pulmonary Disease","2025-10-06",{"date":297,"type":30},"2025-10-08",{"date":299,"type":30},"2025-06-20",{"date":301,"type":21},"2029-08-20",{"name":132,"class":37},15,{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":48,"phases":313,"briefSummary":314,"conditions":315,"keywords":316,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":69},"100565647","the-effect-of-gait-training-using-different-slope-types-on-balance-in-copd-patients-100565647","NCT06644898","The Effect of Gait Training Using Different Slope Types on Balance in COPD Patients","The Effect of Aerobic Exercise Training at Different Slope Types on Balance in COPD Patients","Inclusion Criteria:\n\n* Being diagnosed with COPD (A, B, E groups according to GOLD assessment)\n* Ambulate on your own\n* Not having any contraindications for exercise\n\nExclusion Criteria:\n\n* Being in GOLD 4 stage in spirometric evaluation\n* Presence of hypoxemia\n* Participation in another pulmonary rehabilitation program within the last 6 months\n* Having an exacerbation in the last 1 month\n* Being diagnosed with additional respiratory disease (asthma, bronchiectasis, etc.)\n* Having had pulmonary surgery\n* Having an orthopedic, neurological or cardiac disease that affects exercise\n* Having uncontrolled hypertension or diabetes\n* Presence of malignancy",{"count":312,"type":21},51,[50],"Although COPD is basically a respiratory system disease, its effects are not limited to the respiratory system. In this context, one parameter affected in COPD patients is balance. Recent studies have highlighted the importance of assessing balance and incorporating it into treatment options such as pulmonary rehabilitation. In this context, we aim to diversify the training by using different slope types (downhill, level, uphill) in aerobic exercise training, which is a strong component of pulmonary rehabilitation, and to evaluate the effect of slope type on balance. Testing different types of inclines in aerobic exercise training has the potential to result in different muscular gains. We anticipate that this may result in different balance gains.",[25],[317],"aerobic exercise, slope, COPD","2025-06-10",{"date":320,"type":30},"2025-06-13",{"date":322,"type":30},"2025-04-09",{"date":324,"type":21},"2026-06-01",{"name":326,"class":68},"Acibadem University",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":48,"phases":335,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":338,"startDateStruct":339,"completionDateStruct":340,"leadSponsor":341,"locationsCount":69},"100537836","investigation-of-walking-training-with-different-slope-types-in-copd-patients-100537836","NCT06283004","Investigation of Walking Training With Different Slope Types in COPD Patients","The Effect of Aerobic Exercise Training in Different Slope Types on Exercise Capacity, Respiratory Functions, Muscle Strength, and Functional Status in COPD Patients","Inclusion Criteria:\n\n* Being diagnosed with COPD (A, B, E groups according to GOLD assessment)\n* Ambulate on your own\n* Not having any contraindications for exercise\n* To be mentally appropriate (score 24 points and above in the mini mental test)\n\nExclusion Criteria:\n\n* Being in GOLD 4 stage in spirometric evaluation\n* Presence of hypoxemia\n* Participation in another pulmonary rehabilitation program within the last 6 months\n* Having an exacerbation in the last 1 month\n* Being diagnosed with additional respiratory disease (asthma, bronchiectasis, etc.)\n* Having had pulmonary surgery\n* Having an orthopedic, neurological or cardiac disease that affects exercise\n* Having uncontrolled hypertension or diabetes\n* Presence of malignancy",{"count":312,"type":21},[50],"Chronic obstructive pulmonary disease (COPD) is a disease that continues to generate a great deal of research and this research must continue, both because it is not completely curable and because of the large patient population. The importance and benefits of exercise training in COPD patients are clear. One of the most preferred types of exercise training is the so-called aerobic exercise training, which typically takes the form of walking. A typical walking training does not use a slope or may include an uphill slope. However, recently there have been publications about downhill walking and its benefits in COPD. Walking on a level, uphill, and downhill slope may have the potential to result in different gains by using different muscle groups more. Therefore, this study aimed to compare the effects of walking training on exercise capacity, respiratory functions, muscle strength, and functional status in COPD patients with three different slope types: level, uphill, and downhill.",[25],{"date":320,"type":30},{"date":322,"type":30},{"date":324,"type":21},{"name":326,"class":68},{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":17,"minAge":349,"maxAge":237,"enrollmentInfo":350,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":4},"100580966","early-screening-of-young-copd-and-pre-copd-100580966","NCT06844175","Early Screening of Young COPD and Pre-COPD","A Prospective, Multicenter Cohort Study of Multidimensional Screening and Triple Drug Intervention in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n1\\. Age 20-70 years old; 2. smoking history ≥10 pack-years or presence of visually visible emphysema on low-dose CT scan; 3. Able to tolerate or cooperate with pulmonary function test; ④4.able to understand the study and sign the relevant informed consent.\n\nExclusion Criteria:\n\n1.History of acute or chronic respiratory diseases other than COPD, including interstitial lung disease, bronchiectasis, pulmonary infection, tumor, or lung surgery; 2.patients previously diagnosed with clinical COPD; 3.Severe liver and kidney dysfunction; 4.serious heart failure or malignant arrhythmia; 5.acute cerebrovascular events within the past 3 months; 6.malignant tumor without cure; 7.the history of mental illness; 8.breastfeeding, pregnancy or planned pregnancy; 9.Subjects who are expected to be unable to cooperate and follow up.","20 Years",{"count":351,"type":21},100,"At present, patients with early COPD and pre-COPD have not been paid attention to in clinical work. This study aims to actively screen such patients in high-risk groups to clarify their prevalence, monitor and analyze relevant clinical and biological indicators, and find sensitive indicators to assist in early diagnosis. Based on the updated definition of COPD in GOLD2022, we pay attention to the concept of early COPD and pre-COPD. After the completion of patient enrollment and data collection, we will further explore the effect of triple inhaled drug intervention on the development of lung function in patients with early COPD and pre-COPD, so as to provide clinical support for early screening and early treatment of COPD.\n\n1. Patients with early COPD and pre-COPD were selected from 20 hospitals in 17 cities of Shandong province to understand the prevalence and basic characteristics of such diseases in the province, and then were divided into groups and treated.\n2. The specificity and sensitivity of pulmonary function parameters (FEV1%,FEV1\u002FFVC, DLco, etc.) and imaging parameters (MLD, Perc15, %LAA-950HU, etc.) alone or in combination in the diagnosis of early COPD and pre-COPD, and the predictive diagnostic model\u002Fsystem was established.\n3. Treatment of early COPD and pre-COPD: eligible patients were given triple inhalation therapy or placebo, and the effects of triple inhalation therapy or not on clinical symptoms, pulmonary function, and imaging parameters were compared.\n\nThis study aims to determine the prevalence of early COPD in Shandong province and provide a reference for the treatment of this population.",[25],{"date":355,"type":30},"2025-02-25",{"date":357,"type":21},"2025-03-01",{"date":359,"type":21},"2026-12-30",{"name":361,"class":68},"yanmengkang",{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":69},"100578363","the-roam-research-study-therapy-ltot-version-100578363","NCT06810323","The ROAM Research Study Therapy (LTOT) Version","The Respiratory Oxygen Adherence Monitor System for COPD With Long Term Oxygen Therapy","ROAM","Inclusion Criteria:\n\nPost-Bronchodilator FEV1\u002FFVC \\\u003C.80\n\n* Race demographics of the recruitment area reflect the population of the Charlottesville Metropolitan Statistical Area (MSA).\n* Due to underrepresentation in local demographics, special effort (via targeted advertising) will be made to recruit Hispanic participants to better match national percentages.\n* Participants with medical history of COPD\n* Subjects has to have a prescription for oxygen use via nasal cannula or mask at home\n* At baseline of health with no hospitalization\u002Fexacerbation within the past 6 weeks\n* Use of Continuous oxygen at baseline\n\nExclusion Criteria:\n\nPost -Bronchodilator FEV1 \\\u003C 25%\n\n* Intermittent oxygen use at home\n* Inability to understand simple instructions\n* No respiratory infections and exacerbation within 6 weeks of study",{"count":351,"type":21},"The purpose of this research is to test a device being developed that can see how patients use oxygen therapy over a long period of time. This study will focus on developing a new display part called ROAM module which will be attached to your oxygen source. The display will provide easily-accessible information that can show how you interact with your supplies and the oxygen machine automatically without connecting the oxygen source to the internet or other devices.",[25],"2025-01-30",{"date":375,"type":30},"2025-02-05",{"date":377,"type":30},"2025-01-14",{"date":379,"type":21},"2030-12",{"name":381,"class":68},"University of Virginia",{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":48,"phases":392,"briefSummary":393,"conditions":394,"keywords":395,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":69},"100347711","targeted-nutrient-supplement-in-copd-nutrecover-trial-100347711","NCT03807310","Targeted Nutrient Supplement in COPD (NUTRECOVER-trial)","The Effect of Targeted Nutrient Supplementation on Physical Activity and Healthy Related Quality of Life in COPD","NUTRECOVER","Inclusion Criteria COPD Patients:\n\n* COPD patients with moderate to very severe disease stage according to GOLD criteria (i.e. GOLD stage II-IV);\n* Medically stable.\n\nExclusion Criteria COPD Patients:\n\n* Age \\\u003C18 years;\n* Allergy or intolerance to components of the study product;\n* Not willing or not able to quit vitamin D or fatty acid supplement intake;\n* Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements (e.g. leg amputation) or patients suffering from other acute or unstable chronic diseases that will compromise the study outcome (e.g. active cancer requiring treatment);\n* Participation in any other study involving investigational or marketed products concomitantly or within four weeks prior to entry into the study;\n* Patients with terminal illness;\n* Recent hospital admission (\\\u003C4 weeks prior to the start of the study);\n* Temporary oral steroid or antibiotics use due to a COPD exacerbation in the last 4 weeks;\n* Lung malignancy in the previous 5 years;\n* Diagnosis of dementia or neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease, Huntington's chorea, frontotemporal dementia) in the medical records;\n* Recent diagnosis of cerebral conditions (\\\u003C1 year e.g. cerebral infarction, hemorrhage, brain tumors, transient ischemic attack) in the medical records;\n* Any medical condition that significantly interferes with digestion and\u002For gastrointestinal function (e.g. short bowel syndrome, inflammatory bowel disease, gastric ulcers, gastritis, (gastro)-enteritis, GI-cancer) as judged by the investigator.\n\nInclusion Criteria Healthy Controls\n\n* Forced expiratory volume in 1 second\u002FForced vital capacity \\> 0.7;\n* Medically stable.\n\nExclusion Criteria Healthy Controls\n\n* Age \\\u003C18 years;\n* Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements (e.g. leg amputation) or patients suffering from other acute or unstable chronic diseases that will compromise the study outcome (e.g. active cancer requiring treatment);\n* Participation in any other study involving investigational or marketed products concomitantly or within four weeks prior to entry into the study;\n* Patients with terminal illness;\n* Recent hospital admission (\\\u003C4 weeks prior to the start of the study);\n* Temporary antibiotics use in the last 4 weeks;\n* Lung malignancy in the previous 5 years;\n* Diagnosis of dementia or neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease, Huntington's chorea, frontotemporal dementia) in the medical records;\n* Recent diagnosis of cerebral conditions (\\\u003C1 year e.g. cerebral infarction, hemorrhage, brain tumors, transient ischemic attack) in the medical records;\n* Any medical condition that significantly interferes with digestion and\u002For gastrointestinal function (e.g. short bowel syndrome, inflammatory bowel disease, gastric ulcers, gastritis, (gastro)-enteritis, GI-cancer) as judged by the investigator.\n* Diagnosis of any chronic lung disease.",{"count":391,"type":21},166,[50],"The overall objective is to investigate the efficacy of targeted nutrient supplementation on daily physical activity level as well as generic health status in patients with COPD. Additionally the investigators aim to investigate the relative effect of targeted nutrient supplementation on the recovery after hospitalization for a COPD exacerbation. The secondary objective is to investigate the effect of targeted nutrient supplementation on mental health, physical performance, blood markers, patient related outcomes and gut health. Additionally, a secondary objective is to compare the gut microbiome composition of patients with COPD compared to healthy controls.",[25],[54,396,397,398],"nutrient supplementation","Physical activity","Health related quality of life","2025-01-10",{"date":377,"type":30},{"date":402,"type":30},"2020-02-19",{"date":404,"type":21},"2026-07",{"name":406,"class":68},"Maastricht University Medical Center",{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":11,"sex":17,"minAge":414,"maxAge":106,"enrollmentInfo":415,"targetDuration":4,"studyType":48,"phases":417,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":69},"100570918","efficacy-of-self-titration-of-ventilation-in-overlap-syndrome-chronic-obstructive-pulmonar-disease--sleep-apnea-syndrome--with-dynamic-hyperinflation-edin-idin-100570918","NCT06713486","Efficacy of Self-titration of Ventilation in Overlap Syndrome (chronic Obstructive Pulmonar Disease + Sleep Apnea Syndrome ) with Dynamic Hyperinflation. EDIN-IDIN.","EDIN-IDIN","Inclusion Criteria:\n\n* Stability of at least 4 weeks without hospital admission.\n* Previously presented PCO2 \\> 52.\n* Age between 50 and 80 years.\n* Agree to participate in the study and sign the informed consent.\n* Both sexes.\n\nExclusion Criteria:\n\n* Refusal to participate in the study.\n* Uncontrolled structural or coronary heart disease (no changes in medication in the last 15 days).\n* LVEF \\\u003C 45%.\n* Central sleep apnea syndrome (≥ 50% central events).\n* Uncontrolled pulmonary hypertension.\n* Inability to perform the tests.\n* Having had an exacerbation 4 weeks prior.\n* Severe psychiatric illness.\n* Cognitive impairment.\n* Not speaking Spanish.\n* Illiteracy.\n* Active smoker (or \\\u003C 6 months since quitting smoking).","50 Years",{"count":416,"type":21},20,[50],"The combination of COPD and obstructive sleep apnea (OSA) can lead to undesirable interactions with the treatment approach. The investigators know that continuous positive airway pressure (CPAP) can increase dynamic hyperinflation in COPD patients, and in mechanical ventilation, the increase in PEEP can worsen dynamic hyperinflation. On the other hand, the team know that the severity of COPD obstruction and hyperinflation alter sleep efficiency, with periods of wakefulness during sleep, and during these periods, the patient would not have upper airway obstruction, which could affect the therapy they are receiving in CPAP mode for OSA. Moreover, it was observed that with greater hyperinflation, the rate of obstructive events decreases, dynamically affecting the ventilatory situation with upper airway resistance. Recent studies have determined the safety and efficacy of auto-adjusting systems in the treatment of overlap syndrome, which could be more adaptable to the changing pulmonary mechanics of these patients. Aerobic capacity is a good predictor to the health status in these patients and the investigators know it is reduced in patients with AOS, where CPAP treatment according to studies improves the peak VO2. Therefore, the objective is to compare a ventilation system with fixed pressures established through polysomnography in patients with overlap syndrome and dynamic hyperinflation to a dynamic ventilation system using the fixed pressure limits typically established, based on their impact on the aerobic capacity (peak VO2) of these patients after 1 month of treatment.",[25],"2024-11-27",{"date":422,"type":30},"2024-12-03",{"date":424,"type":21},"2024-12-01",{"date":426,"type":21},"2026-09-01",{"name":428,"class":68},"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia",{"id":430,"slug":431,"hasResults":11,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":436,"targetDuration":4,"studyType":48,"phases":438,"briefSummary":439,"conditions":440,"keywords":441,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":69},"100495354","reducing-the-number-of-hospital-admissions-with-multiple-nursing-interventions-in-copd-patients-using-oxygen-concentrators-at-home-100495354","NCT05730088","Reducing the Number of Hospital Admissions With Multiple Nursing Interventions in COPD Patients Using Oxygen Concentrators at Home","The Effect of Post-Discharge Multiple Nursing Interventions on the Number of Hospital Admissions, Dyspnea Level, and Quality of Life in COPD Patients Receiving Home Oxygen Therapy: A Randomized Controlled Study","Inclusion Criteria:\n\n* Being diagnosed with stage 4 (group D) COPD according to GOLD criteria\n* Being 18 years or older,\n* Having a video computer, tablet or phone,\n* Having an internet connection at home or on the phone,\n* Residing in the city centre of Konya,\n* Not having a communication problem, such as an inability to understand\u002Fspeak Turkish, that would prevent participation in the research,\n* Being literate,\n* Using an oxygen concentrator at home.\n\nExclusion Criteria:\n\n* Being illiterate,\n* Being diagnosed with first, second and third-stage COPD according to GOLD criteria,\n* Having another lung disease in addition to COPD (Lung cancer-Asthma, etc.),\n* Having physical and\u002For mental disabilities,\n* Being visually impaired and\u002For hearing impaired,\n* Having a communication problem that prevents participation in the research, such as an inability to understand\u002Fspeak Turkish,\n* Having been diagnosed with Covid-19 or having had it in the past,\n* Having a psychiatric disease",{"count":437,"type":21},74,[50],"Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by persistent airflow obstruction and chronic respiratory symptoms or alpha-1-antitrypsin deficiency in response to inhaled cigarette smoke or other irritants. The excessive morbidity and mortality associated with COPD acute exacerbations represent a significant public health problem that places a high burden on patients, their families and society. In frequent and severe exacerbations, patients may experience a decrease in quality of life, depression, and even death up to one year after hospitalization. Costs associated with COPD are more than $15.5 billion, and hospitalizations and repeated hospital admissions related to acute exacerbations alone account for 70% of all costs. For these reasons, efforts to reduce hospital admissions and hospitalizations associated with recurrent exacerbations are imperative to improve patient's quality of life and reduce the societal burden.",[25],[54,442,443,444],"home visit","multiple nursing intervention","life quality","2024-11-19",{"date":447,"type":30},"2024-11-22",{"date":449,"type":30},"2023-02-15",{"date":451,"type":21},"2024-12-31",{"name":453,"class":68},"Necmettin Erbakan University",{"id":455,"slug":456,"hasResults":11,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":11,"sex":17,"minAge":461,"maxAge":106,"enrollmentInfo":462,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":473,"locationsCount":69},"100553260","determination-of-factors-effecting-falls-in-patients-with-copd-100553260","NCT06483776","Determination of Factors Effecting Falls in Patients With COPD","Kronik Obstrüktif Akciğer Hastalığında Düşmeye Etki Eden Faktörlerin Belirlenmesi","Inclusion Criteria for Chronic Obstructive Pulmonary Disease Group;\n\n* Being between the ages of 45 and 80,\n* Being literate,\n* Willing to participate in the study,\n* Having COPD classified as stage 1-2-3-4 according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) system,\n* Being clinically stable for the past 4 weeks.\n\nExclusion Criteria for Chronic Obstructive Pulmonary Disease Group;\n\n* Having a history of lung cancer, sarcoidosis, tuberculosis, and\u002For lung surgery,\n* Having any neurological, neuromuscular, vestibular, or cardiac disease that could affect the measurements,\n* Receiving long-term oxygen therapy.","45 Years",{"count":351,"type":21},"The aim of this study is to determine the factors affecting falls in patients with COPD.",[25,465,466],"Fall","Balance; Distorted","2024-06-26",{"date":469,"type":30},"2024-07-03",{"date":471,"type":21},"2024-07-01",{"date":324,"type":21},{"name":474,"class":68},"Hacettepe University",{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":48,"phases":485,"briefSummary":486,"conditions":487,"keywords":488,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":69},"100457368","neuromuscular-fatigue-during-exercise-in-copd-hf-overlap-100457368","NCT05235685","Neuromuscular Fatigue During Exercise in COPD-HF Overlap","Impaired Tissue Oxygen Delivery in Patients With Coexistent COPD-heart Failure: What Consequences on Neuromuscular Fatigue During Exercise?","FIBOX","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* COPD: mild-to-severe airflow obstruction (forced expiratory volume in 1 second (FEV1)\u002Fforced vital capacity ratio \\\u003C0.70; post-bronchodilator FEV1 \\> 30% predicted);\n* HF: reduced left ventricular ejection fraction (\\\u003C50%, for COPD-HF patients only);\n* HF: New York Heart Association Functional Classification I to III (for COPD-HF patients only);\n* Clinical stability for both diseases (COPD and\u002For HF) and no recent (within 3 months) exacerbation requiring a change in medications;\n* Patient benefiting from health care coverage;\n* Patient able to provide written informed consent.\n\nExclusion Criteria:\n\n* Inability to perform cycle ergometry;\n* Medical device incompatible with magnetic stimulation;\n* Counter-indication to perform exercise test;\n* Patient refusing to sign written informed consent;\n* Patient not benefiting from health care coverage;\n* Patient exceeding the annual ceiling of authorized compensation received following participation to a clinical trial;\n* Patient deprived of freedom by judicial or administrative decision;\n* Patient subject to a measure of legal protection (safeguard of justice, guardianship, curatorship), who cannot be included in clinical trials;\n* Pregnant or nursing woman.",{"count":484,"type":21},40,[50],"Rationale. Chronic obstructive pulmonary disease (COPD) and heart failure (HF) coexist in approximately one third of patients presenting with one of these conditions. From a clinical standpoint, impaired tissue oxygen (O2) delivery stands as a common pathological mechanism of these cardiorespiratory diseases. Recent evidence suggest that muscle and cerebral blood flow and oxygenation are further impaired during exercise in patients with COPD-HF overlap compared to isolated diseases. However, it remains unknown whether impaired O2 delivery is associated with exaggerated manifestations of peripheral and central fatigue in COPD-HF overlap. In addition, improving cardiopulmonary interactions through non invasive positive pressure ventilation or through the addition of a hyperoxic gas mixture during exercise have been associated with enhanced cerebral and muscle O2 delivery and oxygenation in patients with COPD or HF. It is, therefore, conceivable that improved O2 delivery to these structures have beneficial influence on exercise capacity in patients with COPD-HF overlap due to less peripheral and central fatigue.\n\nAims. To investigate the influence of impaired O2 delivery during exercise, and its alleviation with different interventions (non invasive positive pressure ventilation or hyperoxia), on neuromuscular fatigue in patients with COPD-HF.",[25,171],[489,490,491,492,493,494],"Exercise Tolerance","Hypoxia, Brain","Muscle Fatigue","Oxygen","Spectroscopy, Near-Infrared","Ultrasonography, Doppler, Transcranial","2024-06-18",{"date":497,"type":30},"2024-06-24",{"date":499,"type":30},"2023-02-21",{"date":501,"type":21},"2025-12",{"name":95,"class":68},{"id":504,"slug":505,"hasResults":11,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":511,"enrollmentInfo":512,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":513,"conditions":514,"keywords":515,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":69},"100267065","the-london-copd-exacerbation-cohort-100267065","NCT02755974","The London COPD Exacerbation Cohort","Relationship Between Patient Phenotypes and Exacerbations in Chronic Obstructive Pulmonary Disease.","EXCEL_Cohort","Inclusion Criteria:\n\n* Forced Expiratory Volume in 1 sec (FEV1)\u002FForced Vital Capacity (FVC) ratio of \\\u003C0.70\n* Able and willing to give informed and written consent\n\nExclusion Criteria:\n\n* Patients with a history of asthma, bronchiectasis, carcinoma of the bronchus, or other significant respiratory disease were excluded.\n* Patients on Immunosuppressive medications or with active cancer\n* Long term steroid therapy\n* Age \\\u003C40 years at recruitment","100 Years",{"count":164,"type":21},"The London COPD exacerbation (EXCEL) cohort builds on an established cohort started in 1995 and designed to study COPD exacerbations and their impact on health-status and disease progression.",[25],[84],"2022-06-16",{"date":518,"type":30},"2022-06-21",{"date":520,"type":30},"2009-01",{"date":522,"type":21},"2026-12-31",{"name":524,"class":68},"Imperial College London",{"id":526,"slug":527,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":48,"phases":534,"briefSummary":535,"conditions":536,"keywords":541,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":69},"100461306","antibiotic-stewardship-in-aecopd-through-crp-guided-management-100461306","NCT05286918","Antibiotic Stewardship in AECOPD Through CRP-Guided Management","Antibiotic Stewardship Through CRP-guided Antibiotic Treatment for Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)","Inclusion Criteria:\n\n1. Being diagnosed with active AECOPD (AECOPD is defined as an event in the natural course of a disease characterized by a change in baseline dyspnoea, cough, and\u002For sputum that is beyond the normal day-to-day variations with acute onset, which may warrant a change in regular medication in patients with underlying COPD).\n2. Known COPD in their medical records.\n3. Age 40 years or older.\n4. Able to provide informed consent in Cantonese, Mandarin, or English\n5. Able to complete the questionnaires during the study period (i.e. 6 months after randomisation)\n\nExclusion Criteria:\n\nPatients will be excluded if any ONE of the following are present:\n\n1. Pre-treatment with systemic corticosteroids for the present exacerbation.\n2. Pre-treatment with any antibiotics for the present exacerbation, any concurrent infection or prophylaxis.\n3. Known clinical stroke in past 6 months\n4. Patients with high suspicion of active AECOPD mimics:\n\n   1. Pneumonia\n   2. Congestive heart failure\n   3. Bronchiectasis\n   4. Pulmonary embolism\n   5. Pneumothorax\n   6. Atrial fibrillation \u002F flutter\n5. Lung comorbidities:\n\n   1. Cystic fibrosis\n   2. Tuberculosis\n   3. Unresolved lung malignancy\n6. Progression or new radiographic abnormalities on the chest X-ray.\n7. Immunodeficiency disorders such as AIDS, humoral immune defect, ciliary dysfunction etc., and the use of immunosuppressive drugs for more than 28 days.\n8. Active inflammatory condition (e.g. flare up of rheumatoid arthritis, gout or polymyalgia rheumatica) or concurrent infection at another site (e.g. UTI, cellulitis) that is likely to produce a systemic response\n9. Currently pregnant\n10. NEWS2 score of ≥3",{"count":533,"type":21},1184,[50],"Objectives:\n\nTo determine whether CRP-guided antibiotic treatment for managing AECOPD in adult patients attending Emergency Departments leads to reduced antibiotic duration, without non-inferior COPD health status with usual care.\n\nHypothesis to be tested:\n\n(i) The antibiotic duration in AECOPD patients will be significantly lower for CRP-guided antibiotic discontinuation than usual care; and (ii) COPD health status as measured by the Clinical COPD Questionnaire has no statistically significant difference between two groups.\n\nDesign and subjects:\n\nMulti-center, single-blind, open-label, randomized, combined superiority (antibiotic duration) and non-inferiority (COPD health status) trial in 1,184 adult AECOPD patients presented to A\\&E.\n\nInstruments:\n\nClinical COPD Questionnaire and EuroQol-5D\n\nInterventions:\n\nBoth intervention and control groups follow usual care with GOLD strategy. The intervention group will be recommended to test for serum CRP daily. Antibiotic prescription is considered when CRP \\>5mg\u002FdL. Once CRP has declined to \\\u003C5mg\u002FdL and the patient was afebrile for past 48 hours, antibiotic discontinuation will be considered.\n\nCommunication with Receiving Ward Staffs:\n\nParticipants in the study may transfer to another departments after treatment\u002F care in A\\&E. The following communication would be conducted:\n\n* A handover note that informs the receiving ward staffs about patients' enrolment to the trial, group assignment, and previous treatments given in A\\&E. The note would also suggest the investigations for the receiving ward staffs.\n* Telephone handover about intervention group and investigations of the study, and treatments given in A\\&E to ward.\n\nMain outcome measures:\n\nThe antibiotic duration (total number of antibiotic days) within 28 days and recovery in terms of COPD health status (Clinical COPD Questionnaire total scores) within 14 days from randomisation.\n\nData analysis:\n\nIntention-to-treat and cost-effectiveness analyses will be performed. The outcome assessors and data analysts will be blinded to group allocation.\n\nExpected results:\n\nThe intervention group will exhibit reduction in antibiotic duration at 4-weeks, without negatively impacting on COPD health status, compared with the control group.",[537,538,539,25,540],"Acute Exacerbation of COPD","Lung Diseases","Lung Diseases, Obstructive","Respiratory Tract Disease",[54,542,543,544,545],"Antibiotics","C-Reactive Protein","Antibiotic stewardship","Emergency Department","2022-05-16",{"date":548,"type":30},"2022-05-23",{"date":550,"type":21},"2022-09-01",{"date":552,"type":21},"2026-08-31",{"name":554,"class":68},"The University of Hong Kong"]